Download ppt - Surgical Oncology

Transcript
Page 1: Surgical Oncology

SURGICAL ONCOLOGY

James Taclin C. Banez, MD, FPSGS, FPCS, DPBS, DPSA

Page 2: Surgical Oncology

Study of neoplastic diseases: ONCOS = tumor LOGOS = study

Neoplasm: Altered cell population characterized by

an excessive, non-useful proliferation of cells that are unresponsive to normal control mechanisms and to organizing influences of adjacent tissue.

Page 3: Surgical Oncology

Neoplasm:1. Malignant:

Cancer cells that exhibit uncontrolled proliferation and impair the function of normal organs by local tissue invasion and metastatic spread to distant anatomic sites.

2. Benign: Composed of normal appearing cells

that do not invade locally or metastasize to other sites

Page 4: Surgical Oncology

EPIDEMIOLOGY:

Overall cancer death rates shows slow steady increase

Lower death rates during past 50yrs:

1. Stomach2. Uterus

Increase death rates:1. Lung2. Pancreas

Page 5: Surgical Oncology

EPIDEMIOLOGY:Cancer incidence by sites and sex:

Male Female

Lung 20% Breast 27%

Prostate 20% Colon & Rectum 16%

Colon & Rectum 14% Lung 11%

Urinary 10% Uterus 10%

Leukemia & Lymphoma

8%Leukemia & Lymphoma

7%

Skin, pancreas and oral

3-4%Skin, pancreas and oral

3-4%

Page 6: Surgical Oncology

EPIDEMIOLOGY:Cancer death by sites and sex:

Male Female

Lung 36% Lung 20%

Colon & Rectum 11% Breast 18%

Prostate 10% Colon & Rectum 14%

Leukemia & Lymphoma

9%Leukemia & Lymphoma

9%

Pancreas & Urinary

5% each

Pancreas & Ovary 5%

Urinary & Uterus4%

each

Page 7: Surgical Oncology

The most significant 5 yrs survival rates are achieved in patients w/ cancer of skin, thyroid, cervix, uterus and bladder; w/ the lowest survival w/ pancreatic cancer

Females tend to have a greater number of 5yrs survival w/ cancer of any given primary site than males, reason (?)

5 yr survival female = 50%5 yr survival male = 31%

Page 8: Surgical Oncology

ETIOLOGY:1. Chemical carcinogens:

a. Hydrocarbons from coal tar = skin, larynx & bronchial CA

b. Aromatic amines = urinary tract CAc. Benzene = leukemiad. Asbestos = mesothelioma

2. Physical carcinogens:a. Ionizing radiations = bone cancer

Multiple x-rays = skin/thyroid CA

b. Atomic bomb (Japan) = leukemia

Page 9: Surgical Oncology

ETIOLOGY:3. Mechanical (chronic irritation):

Marjolin’s ulcer = burn scar cancer

4. Infection: Parasitic:

Schistosomas – Liver & bladder CA Viruses:

Hepatitis B – hepatocellular CA Epstein-Barr virus – Burkitts lymphoma Herpes simplex virus 2 – cervical CA Aids

Page 10: Surgical Oncology

ETIOLOGY:5. Geographic factors:

Inc. CA of stomach – Scandinavian,Iceland and Japan

Inc. CA of liver – South & West Africa Inc. CA of Nasopharynx – China Inc. CA of urinary bladder – Egypt Dec. CA of colon – Black/Africa Dec. CA prostate / breast – Japan Dec. CA of uterine/cervix – Israel/Jewish Dec. CA of skin – Blacks

customs & environment plays an important role in the development of CA.

migration of populations usually causes a shift towards the patterns of cancer incidence of the host country

Page 11: Surgical Oncology

ETIOLOGY:6. Precancerous conditions:

a. Leucoplakiab. Actinic keratosisc. Polyps of colon & rectumd. Neurofibromase. Dysplasia of cervix, bronchialf. Chronic ulcerative colitis

7. Hereditary factors: Familial polyposis – colonic CA6. Breast CA – 2-3x in daughters and in

younger age

Page 12: Surgical Oncology

ETIOLOGY:8. Oncogenes & Growth Factors:

RNA tumor viruses cause: 1. Carcinomas2. Sarcoma3. Leukemia4. Lymphomas

Retrovirus have an enzyme that alters genomic RNA resulting to abnormal growth and differentiation of the cell.

9. Multi-factorial: Lung / breast CA

Page 13: Surgical Oncology

CANCER BIOLOGY1. Morphologic changes:

Rise from a single cell Revert to more primitive cell types Normal orderly tissue patterns are lost

or replaced by the random pilling up of malignant cells w/o definite pattern

High index of mitoses Invasion of adjacent structures

Page 14: Surgical Oncology

CANCER BIOLOGY2. Biochemical changes:

Changes in DNA, RNA and chemical architecture results to LOSS of CONTACT INHIBITION to proliferation and intercellular adhesiveness

Reversion of normal cellular biochemistry to that of the embryonal cells that produces EMBRYONAL subs. (CEA, alpha fetoprotein)

Page 15: Surgical Oncology

CANCER BIOLOGY

2. Biochemical changes: Also produced biologically active subs.

Normally produced by the cells. (hyperparathyroidism); also that are not normally produced by the cells of origin (bronchogenic CA=ACTH)

3. Growth rates of neoplasm: Doubling time is doubled Takes 30 doubling time to produce

1cm nodule

Page 16: Surgical Oncology

CANCER BIOLOGY4. Effector mechanism in tumor

immunity: Host provides a number of effector

mechs. that destroys the tumor:a. Tumor-antigen-specific antibodiesb. Mononuclear phagocytesc. Natural killer cellsd. Cytotoxic T lymphocytese. Neutrophilsf. K cells

Page 17: Surgical Oncology

CANCER BIOLOGY4. Effector mechanism in tumor

immunity: Tumor Necrosis Factor (TNF):

Cytokines produced by monocytes, machrophage, endothelial cells, large granular lymphocytes and neutrophils

Properties:a. Direct cytotoxicity for certain cellsb. Stimulation of procoagulant activity by

vascular endothelial cellsc. Induction of fever by direct effect on the

hypothalamic thermoregulatory center

Page 18: Surgical Oncology

CANCER PATHOLOGY

A. Classification of Neoplasm:

Carcinoma – arising from epithelial cells

Sarcoma – arise from connective tissue and cells of mesenchymal origin (fibrous, muscular, fatty, vascular & skeletal).

Page 19: Surgical Oncology

CANCER PATHOLOGYB. Grading of malignancy:

Broders classified carcinoma into 4 grades according to:1. Degree of differentiation2. Appearance of cells, their nuclei and

the number of mitotic figures

Grade I – least malignantGrade IV – most malignant

Page 20: Surgical Oncology

CANCER PATHOLOGY

Carcinoma in Situ:Has cytologic characteristic of

malignant tumors but w/ no detectable invasion into the surrounding tissue or infiltration into deeper cell layers

Page 21: Surgical Oncology

ROUTES OF SPREAD: Metastasis may entirely dominate

the clinical picture, while the primary tumor remains latent and asymptomatic

1. Direct extension2. Lymphatic spread

Common in epithelial neoplasms of all types (except for basal cell CA)

Page 22: Surgical Oncology

ROUTES OF SPREAD:

3. Vascular spread Either thru the thoracic duct or by the

invasion of blood vessels Capillaries are almost invaded, veins

invaded frequently but arteries rarely. More common in sarcomas

4. Spread through serous cavities Peritoneal seedings (gastrointestinal CA)

Page 23: Surgical Oncology

CLINICAL MANIFESTATION: The onset of neoplastic state is

difficult to date (asymptomatic).Seven Danger Signals of Cancer

(Direct manifestation):1. Change in bowel or bladder habits2. A sore that does not heal3. Unusual bleeding or discharge4. Thickening or lump in breast or

elsewhere5. Indigestion or difficult in swallowing6. Obvious change in wart or mole7. Nagging cough or hoarseness

Page 24: Surgical Oncology

CLINICAL MANIFESTATION:Indirect or Systemic Manifestation:

1. Secondary to metastasis Cachexia

2. Secondary to none metastatic:a. Ectopic production of known hormonesb. Secretion of unidentified, hormone like

substancesc. Toxic substances secreted from the tumord. Autoimmune – host is sensitized to an

antigen from the tumor

Page 25: Surgical Oncology

CLINICAL MANIFESTATION:Signs of Expansile growth:1. Obstruction2. Destruction

Signs of Infiltrative Growth: Tumor infiltrates the nerves

1. Pain2. Numbness3. paralysis

Page 26: Surgical Oncology

CLINICAL MANIFESTATION:Signs of Tumor necrosis (Bleeding &

Infection): Tumor may become necrotic, ulcerate

and bleed Fatigue and weakness in right colon

cancer due to anemia Inflammation caused by cecal CA can

mimic the clinical symptoms of acute AP or cholecystitis.

Unknown primary tumors presenting as metastases

Page 27: Surgical Oncology

DIAGNOSIS OF CANCER:

A. Clinical History: Warning signs for Cancer:

1. Weight loss2. Loss of Appetite3. Bleeding or a discharge from any

body orifice or nipple4. Sore that is slow to heal

Page 28: Surgical Oncology

DIAGNOSIS OF CANCER:

A. Clinical History: Warning signs for Cancer:5. Persistent cough or wheeze6. Change in voice7. Difficulty of swallowing8. Change in bowel habit9. Growing lump in the skin, breast,

abdomen or muscle

Page 29: Surgical Oncology

DIAGNOSIS OF CANCER:

B. Physical Examination: Palpable masses (movable, non-

movable) LN enlargement

C. Laboratory Examination: Blood examination Radiological procedure:

X-ray, esophagoram, Barium enema, mammography, thyroid scan, CT scan, MRI

Page 30: Surgical Oncology

DIAGNOSIS OF CANCER:

C. Laboratory Examination: Endoscopy:

Bronchoscopy, esophagoscopy, gastroscopy, proctosigmoidoscopy, colonoscopy, cystoscopy

Page 31: Surgical Oncology

DIAGNOSIS OF CANCER:

C. Laboratory Examination: Biopsy:

To document presence of malignancy Types:

1. Needle biopsy (cytological)2. Incisional biopsy3. Excisional biopsy

o Rapid frozen biopsy / exfoliative cytology (Pap smear)

Page 32: Surgical Oncology

STAGING OF CANCER:

A. Clinical Staging of Cancer:TNM:

Stage I = cancer confined to it’s primary site

Stage II = more locally advanced disease

Stage III = metastasis to regional LN

Stage IV = metastasis to distant sites

Use all information available prior to 1st definitive treatment:

Page 33: Surgical Oncology

STAGING OF CANCER:

B. Post-surgical Resection Staging: Pathological Staging:

The extent of disease using all data available at the time of surgery and on examination of a completely resected specimen.

C. Re-treatment Staging: Restaging is necessary for additional or secondary

definitive treatment after a (disease-free) interval following 1st treatment.

D. Autopsy Staging: Used only when the cancer is 1st diagnosed at

autopsy.

Page 34: Surgical Oncology

CANCER TREATMENT:

Interdisciplinary Approach:1. Surgical resection 55% (40% alone)

2. Radiation therapy 34% (16% alone)

3. Chemotherapy 22% (alone or combination)

Surgery & radiation tx represents treatment of cancers that remains localized to it’s primary site or regional LN.

Chemotherapy and Immunotherapy – tx effective against tumor cells already metastatic to distant organ sites.

Page 35: Surgical Oncology

CANCER TREATMENT:

GOALS of Therapy: Vary w/ extent of the cancer:

1. Localized w/o evidence of spread: Eradicate the cancer and CURE

THE PATIENT2. Spread beyond the local site:

Control patient’s symptoms and to maintain maximum activity for the longest possible period of time.

Page 36: Surgical Oncology

CANCER TREATMENT:

CRITERIA of Incurability:1. Distant metastasis (most common)2. Evidence of extensive local

infiltration of adjacent organs or structures

Pt’s general condition and the presence of any co-existing disease must be considered in planning therapy.

The PSYCHOLOGICAL makeup of the patient and the patient’s life situation must be considered.

Page 37: Surgical Oncology

CANCER TREATMENT:SURGICAL RESECTION:A. Surgical Curative Resection:

Wide local resection: Low grade malignancy Basal cell CA of the skin

Radical Local Resection: High grade malignancy En Bloc LN dissection for breast,

esophagus, gastric, colorectal CA

B. Surgical Palliative Resection:1. To relieve symptoms2. To prolong a useful comfortable life3. Gastrojejunostomy, colostomy

Page 38: Surgical Oncology

CANCER TREATMENT:

RADIOTHERAPY: Destroy tumor with preservation of

anatomic structures Direct toxic effect to cells due to

ionization of water

Page 39: Surgical Oncology

CANCER TREATMENT:

CHEMOTHERAPY:Antimetabolites:

Inhibit enzymes of nucleic acid synthesis Methotrexate & 5-FU

Alkylating agents: Substitute alkyl grp for the hydrogen

atom Alkylation of DNA molecule interferes

with replication in transcription

Page 40: Surgical Oncology

CANCER TREATMENT:

CHEMOTHERAPY:Antibiotics:

From soil fungi Forms stable complexes with DNA and

inhibit synthesis of DNA and RNA Actinomycin D, Doxorubicin, Bleomycin

Vinca Alkaloids: Bind to microtubular proteins necessary

for cell division causing cell death during mitosis

Vincristine & Vinblastine

Page 41: Surgical Oncology

CANCER TREATMENT:

IMMUNOTHERAPY: Inhibit proliferation of cancer cells w/o

affecting function of normal cells Stimulates the host to generate specific

immune response to its tumor-vaccine from tumor cells

TUMOR SPECIFIC ANTISERUM: Murine monoclonal antibodies Immunotoxins

None-specific immunotherapy=BCG vaccine

Page 42: Surgical Oncology

PROGNOSIS:

DETERMINANTS:1. Site of origin of primary tumor2. Stage of the disease3. Histologic features of the cancer4. Host immune factors5. Age of the patients

Page 43: Surgical Oncology

THANK YOU


Recommended